公开(公告)号：EP2873417A4

公开(公告)日：2016-03-09

申请号：EP13816500

申请日：2013-07-03

申请人： SBI PHARMACEUTICALS CO LTD ,  NAT CT FOR CHILD HEALTH AND DEV

发明人： TANAKA TOHRU ,  NAKAJIMA MOTOWO ,  ABE FUMINORI ,  HAGA NAOMI ,  TAKAHASHI KIWAMU ,  ITO HIDENORI ,  RII KO

IPC分类号： A61K31/197 ,  A61K31/194 ,  A61K33/26 ,  A61K38/19 ,  A61P17/00 ,  A61P37/06 ,  A61P37/08

CPC分类号： A61K31/197 ,  A61K31/194 ,  A61K33/26 ,  A61K38/193 ,  A61K38/40 ,  C12N5/064 ,  C12N2500/24 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/2304 ,  A61K2300/00

摘要： An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of the 5-ALA or the derivative and an iron compound as active ingredients is prepared. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

公开(公告)号：EP2767278A4

公开(公告)日：2015-04-08

申请号：EP12839496

申请日：2012-09-12

申请人： SBI PHARMACEUTICALS CO LTD ,  NAT CT FOR CHILD HEALTH AND DEV

发明人： RII KO ,  TAKAHASHI KIWAMU ,  HAGA NAOMI ,  ABE FUMINORI ,  TANAKA TOHRU ,  NAKAJIMA MOTOWO ,  ITO HIDENORI

IPC分类号： A61K31/197 ,  A61K31/22 ,  A61K31/295 ,  A61K33/26 ,  A61P37/06

CPC分类号： A61K31/197 ,  A01N1/0226 ,  A61K31/22 ,  A61K31/295 ,  A61K33/26 ,  A61K35/17 ,  A61K45/06 ,  A61K2035/122 ,  A61K2035/124 ,  A61K2300/00

摘要： The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.

公开(公告)号：EP2875812A4

公开(公告)日：2016-02-24

申请号：EP13823261

申请日：2013-07-11

申请人： UNIV TOKYO ,  SBI PHARMACEUTICALS CO LTD

发明人： TANAKA TOHRU ,  NAKAJIMA MOTOWO ,  ABE FUMINORI ,  ITO HIDENORI ,  TAKAHASHI KIWAMU ,  MATSUSHIMA KOUJI ,  UEHA SATOSHI ,  ABE JUN

IPC分类号： A61K31/195 ,  A61K31/16 ,  A61K31/197 ,  A61K31/22 ,  A61K31/24 ,  A61K31/555 ,  A61K33/26 ,  A61K45/00 ,  A61K45/06 ,  A61P7/00 ,  A61P39/00 ,  A61P43/00

CPC分类号： A61K31/197 ,  A61K31/22 ,  A61K31/24 ,  A61K31/555 ,  A61K33/26 ,  A61K45/06 ,  A61K2300/00

摘要： An object of the present invention is to provide a preventive and/or therapeutic agent for radiation damage that has a novel mechanism of action and can prevent and alleviate a wide range of symptoms of radiation damage for which no therapeutic measures have been available so far, and moreover, is highly safe to humans. A preventive and/or therapeutic agent for radiation damage comprising a compound represented by the following formula (I) such as 5-aminolevulinic acid (5-ALA) or a salt thereof as an active ingredient can be used to improve the survival rate, improve body weight reduction, and alleviate hematopoietic disorder: (wherein R 1 represents a hydrogen atom or an acyl group; and R 2 represents a hydrogen atom, a linear or branched alkyl group, a cycloalkyl group, an aryl group, or an aralkyl group).

公开(公告)号：EP3150067A4

公开(公告)日：2017-11-08

申请号：EP15799853

申请日：2015-02-24

申请人： SBI PHARMACEUTICALS CO LTD ,  NAT CENTER FOR CHILD HEALTH AND DEV

发明人： TANAKA TOHRU ,  NAKAJIMA MOTOWO ,  OTA URARA ,  ITO HIDENORI ,  RII KO

IPC分类号： A01N1/02

CPC分类号： A01N1/0226 ,  A01N1/02

摘要： Provided is an organ preservation solution for use in transplantation, which is capable of effectively preventing the occurrence of ischemia-reperfusion injury. Prepared is an organ preservation solution comprising a mixture of the following components: (a) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, and D-glucose; (b) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, glycine, and D-glucose; (c) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, and D-glucose; or (d) potassium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, L-ascorbic acid, L-ascorbic acid phosphate ester, L-cysteine, glycine, an iron compound, and D-glucose.